Characteristics of patients with pancreatic cancer expressing a novel cancer cachectic factor

British Journal of Surgery

Volumn 87, Issue 1, 2000, Pages 53-58

  Wigmore, S J ^a   Todorov, P T ^b   Barber, M D ^a   Ross, J A ^a   Tisdale, M J ^b   Fearon, K C H ^a  

^a ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

^b ASTON UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE PHASE PROTEIN; C REACTIVE PROTEIN; GLYCOPROTEIN; MONOCLONAL ANTIBODY; PYROXYLIN;

ADULT; AGED; ARTICLE; BODY WEIGHT; CACHEXIA; CANCER SURVIVAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NUTRITION; PANCREAS CANCER; PRECIPITATION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN URINE LEVEL; ULTRAFILTRATION; URINALYSIS; WEIGHT REDUCTION; WESTERN BLOTTING;

AGED; AGED, 80 AND OVER; BLOOD PROTEINS; BODY COMPOSITION; C-REACTIVE PROTEIN; CACHEXIA; ENERGY METABOLISM; HUMANS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; PANCREATIC NEOPLASMS; SURVIVAL ANALYSIS; WEIGHT LOSS;

EID: 0033988122     PISSN: 00071323     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2168.2000.01317.x     Document Type: Article

References (17)

1. 1 Ovesen L, Hannibal J, Mortensen EL. The interrelationship of weight loss, dietary intake, and quality of life in ambulatory patients with cancer of the lung, breast, and ovary. Nutr Cancer 1993; 19: 159-67.
2. 2 De Wys WD, Begg C, Lavin PT, Band PR, Bennett JM, Bertino JR et al. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Am J Med 1980; 69: 491-7.
3. 3 Wigmore SJ, Plester CE, Ross JA, Fearon KCH. Contribution of anorexia and hypermetabolism to weight loss in anicteric patients with pancreatic cancer. Br J Surg 1997; 84: 196-7.
4. 4 Falconer JS, Fearon KCH, Plester CE, Ross JA, Carter DC. Cytokines, the acute-phase response, and resting energy expenditure in cachectic patients with pancreatic cancer. Ann Surg 1994; 219: 325-31.
5. 5 Mullen JL. Hypermetabolism and advanced cancer. Ann Surg 1994; 219: 323-1 (Editorial).
6. 6 Ng E-H, Lowry SF. Nutritional support and cancer cachexia. Evolving concepts of mechanisms and adjunctive therapies. Hematol Oncol Clin North Am 1991; 5: 161-84.
7. 7 Moldawer LL, Copeland EM III. Proinflammatory cytokines, nutritional support, and the cachexia syndrome. Interactions and therapeutic options. Cancer 1997; 79: 1828-39.
8. 8 Fearon KCH, Preston T. Body composition in cancer cachexia. Infusionstberapie 1990; 17(Suppl 3): 63-6.
9. 9 McDevitt TM, Todorov PT, Beck SA, Khan SH, Tisdale MJ. Purification and characterization of a lipid-mobilizing factor associated with cachexia-inducing tumors in mice and humans. Cancer Res 1995; 55: 1458-63.
10. 10 Todorov P, Cariuk P, McDevitt T, Coles B, Fearon K, Tisdale MJ. Characterization of a cancer cachectic factor. Nature 1996; 379: 739-42.
11. 11 Todorov PT, McDevitt TM, Cariuk P, Coles B, Deacon M, Tisdale MJ. Induction of muscle protein degradation and weight loss by a tumor product. Cancer Res 1996; 56: 1256-61.
12. 12 Cariuk P, Lorite MJ, Todorov PT, Field WN, Wigmore SJ, Tisdale MJ. Induction of cachexia in mice by a product isolated from the urine of cachectic cancer patients. Br J Cancer 1997; 76: 606-13.
13. 13 Todorov PT, Deacon M, Tisdale MJ. Structural analysis of a tumor-produced sulfated glycoprotein capable of initiating muscle protein degradation. J Biol Chem 1997; 272: 12 279-88.
14. 14 Jelliffe DB. The Assessment of Nutritional Status of the Community (with Special Reference to Field Surveys in Developing Regions of the World). WHO Monograph 53. Geneva: World Health Organization: 1966.
15. 15 Hannan WJ, Cowen SJ, Plester CE, Fearon KCH, deBeaux A. Comparison of bio-impedance spectroscopy and multi-frequency bio-impedance analysis for the assessment of extracellular and total body water in surgical patients. Clin Sci 1995; 89: 651-8.
16. 16 Wigmore SJ, Plester CE, Richardson RA, Fearon KCH. Changes in nutritional status associated with unresectable pancreatic cancer. Br J Cancer 1997; 75: 106-9.
17. 17 Falconer JS, Fearon KCH, Ross JA, Elton R, Wigmore SJ, Garden OJ et al. Acute-phase protein response and survival duration of patients with pancreatic cancer. Cancer 1995; 75: 2077-82.